Boston Scientific
BSX
41.98
-1.01
-2.35%
Boston Scientific
US · BSX
#364 by market cap
Listed 1970
41.98
-1.01
-2.35%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 7 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.2 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.58% -0.17pp
- Institutions
- 1,910 -7
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund76.28%
Hedge Fund8.43%
Public Company3.71%
Government Pension Fund2.22%
Private Company1.68%
Sovereign Wealth Fund1.58%
VC/PE Fund0.41%
Endowment Fund0.33%
Insurance Company0.21%
Corporate Pension Plan0.30%
Other5.05%
Top holders as of 2026-09-30
BlackRock
8.66% · 125.56M sh
Vanguard Capital Management, LLC
7.11% · 103.09M sh
State Street Global Advisors
4.64% · 67.32M sh
PRIMECAP Management Company
4.04% · 58.62M sh
Capital Research
3.23% · 46.86M sh
Other
72.73%
Vanguard Portfolio Management, LLC
3.13% · 45.39M sh
MFS Investment Management
2.97% · 43.05M sh
Geode Capital Management, LLC
2.38% · 34.47M sh
FMR
2.13% · 30.95M sh
UBS Asset Management
2.03% · 29.44M sh
D. E. Shaw & Co., L.P.
1.76% · 25.46M sh
Arrowstreet Capital, Limited Partnership
1.96% · 28.47M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Michael Mahoney | Chairperson & CEO | 0.13% |
| Joseph Fitzgerald | Executive VP & Group President of Cardiovascular | 0.02% |
| Daniel Brennan | Former Chief Financial Officer | 0.01% |
| Arthur Crosswell Butcher | Executive VP and Group President of MedSurg & Asia Pacific | 0.01% |
| Jeffrey Mirviss | Former Senior VP & President of Peripheral Interventions | 0.00% |
| Charles Dockendorff | Former Independent Director | 0.00% |
| John Sununu | Former Independent Director | 0.00% |
| Vance Brown | EVP, General Counsel & Corporate Secretary | 0.00% |
| Jonathan Monson | Chief Financial Officer | 0.00% |
| David Wichmann | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-03 | Michael Mahoney | Chairperson & CEO | Other Acquisition | +252,241 | -- |
| 2026-10-31 | Miriam O'sullivan | -- | Derivative Exercise and Sale | -1,872 | $41.98 |
| 2026-10-31 | Miriam O'sullivan | -- | Derivative Exercise and Retained | +1,999 | -- |
| 2026-09-01 | Padraig O'Connor | -- | Derivative Exercise and Sale | -567 | $48.37 |
| 2026-09-01 | Padraig O'Connor | -- | Derivative Exercise and Retained | +604 | -- |
| 2026-08-24 | Susan Morano | Independent Director | Open Market Acquisition | +2,040 | $49.22 |
| 2026-08-10 | Emily Woodworth | Senior VP, Global Controller & Chief Accounting Officer | Acquisition Under Employee Benef | +2,930 | $51.19 |
| 2026-08-09 | Jonathan Monson | Chief Financial Officer | Acquisition Under Employee Benef | +9,908 | $50.46 |
| 2026-08-04 | David Habiger | Independent Director | Open Market Acquisition | +2,100 | $47.59 |
| 2026-08-03 | David Habiger | Independent Director | Open Market Acquisition | +1,182 | $48.07–48.59 |
| 2026-08-02 | Michael Mahoney | Chairperson & CEO | Open Market Acquisition | +186,240 | $48.33 |
| 2026-08-02 | Michael Mahoney | Chairperson & CEO | Acquisition Under Employee Benef | +22,119 | $48.43 |
| 2026-07-30 | Edward Ludwig | Lead Independent Director | Open Market Acquisition | +5,000 | $45.48 |
| 2026-07-30 | Joseph Fitzgerald | Executive VP & Group President of Cardiovascular | Acquisition Under Employee Benef | +64,198 | $46.73 |
| 2026-06-30 | Jonathan Monson | Chief Financial Officer | Derivative Exercise and Sale | -1,010 | $43.06 |
| 2026-06-30 | Jonathan Monson | Chief Financial Officer | Derivative Exercise and Retained | +1,077 | -- |
| 2026-05-27 | Michael Mahoney | Chairperson & CEO | Other Disposition | -386,755 | -- |
| 2026-05-19 | Edward Ludwig | Lead Independent Director | Open Market Acquisition | +3,580 | $56.68 |
| 2026-05-19 | Cheryl Pegus | Independent Director | Open Market Acquisition | +1,770 | $56.49 |
| 2026-05-19 | David Habiger | Independent Director | Open Market Acquisition | +4,450 | $55.92–56.95 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Boston Scientific discussion 0 comments